Spot-Scanning Proton Therapy Patient-Specific Quality Assurance: Results from 309 Treatment Plans [PDF]
Dennis Mackin +14 more
openalex +1 more source
First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena +5 more
wiley +1 more source
Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma. [PDF]
Jiang C +15 more
europepmc +1 more source
Error identification and compensation in large manipulators with application in cancer proton therapy [PDF]
Marco Antônio Meggiolaro +2 more
openalex +1 more source
This study identifies vacuole membrane protein 1 (VMP1) as a critical regulator of intestinal epithelial barrier homeostasis. VMP1 facilitates the recruitment of CORO1C to late endosomes, supporting Retromer‐mediated recycling of the tight junction protein Occludin.
Jiawei Zhao +12 more
wiley +1 more source
Fluorescent nuclear track detectors for out-of-field neutron dosimetry in proton therapy. [PDF]
Schmidt S +3 more
europepmc +1 more source
Fiducial Markers, Saline, and Balloons to Locate and Stabilize the Prostate during Proton Therapy
R. A. Zeitlin +9 more
openalex +1 more source
Power Calculation And Design Considerations For Randomized Controlled Trials Testing Toxicity Reduction With Proton Therapy In Head And Neck Cancer [PDF]
A. van der Schaaf +7 more
openalex +1 more source
The 10B‐enriched monocarbonyl analog of curcumin (BMAC) 10B‐9 enables site‐specific Boron Neutron Capture Therapy (BNCT) on amyloid‐β (Aβ) fibrils. Neutron irradiation induces histidine oxidation and fibril destabilization, as revealed by 1H‐NMR and FESEM analyses.
Sebastiano Micocci +12 more
wiley +1 more source
Feasibility of reduced setup uncertainty in intensity-modulated proton therapy for mediastinal lymphoma. [PDF]
Pisciotta P +9 more
europepmc +1 more source

